Cellagen® - Transforming Age-Related Medicine with Cell Therapeutics
GeriGene's focus on the science of aging offers important medical, social and financial benefits. Already the costs of taking care of the aged are overwhelming. And frequently, the results of existing treatments are less than effective.
Understanding aging at the molecular level makes it possible to design new tools that combat its effects. The medical benefits improve vitality, lifestyle and the cost-effectiveness of caring for individual patients. Across a broad and growing population of aging people, more effective therapeutics can help drive down the costs of healthcare and its negative impacts on the economy and family life.
GeriGene can introduce its medical therapies into the healthcare system as it currently exists. Yet its foundation of research will also allow parallel product development as healthcare inevitably changes.
GeriGene's discoveries in such fields as genetics, biochemistry, molecular biology and cell biology all hold new promise to address the mysteries of aging.
The Cell Therapeutic Approach, Cellagen®
Most biotechnology companies are developing products that require 7 to 10 years of research, development and clinical trials for FDA approval. The companies aim to create blockbuster products or platforms. Their goal is to either license the inventions to a pharmaceutical company that itself is operating in the blockbuster business model, or to become a small pharmaceutical concern.
The length of time and the complexity of this business model create many challenges. The GeriGene Cellagen® products are supported by five business strategies to short-circuit the current market model and optimize risks for early and developmental stage investors.
First, the company is addressing large markets with unmet needs.
Second, its platform technology may require much shorter FDA approval times and lower-cost clinical trial pathways.
Third, these products have profit potential to support additional growth in product applications, geography and new therapeutic areas.
Fourth, GeriGene will keep low overhead and remain agile in its management structure.
Fifth, the company can license some or all of its initial product offerings, or commercialize them on its own, for the benefit of shareholders.
GeriGene is poised to initiate new clinical studies quickly. It has the flexibility to develop unique collaborations with academic institutions, research organizations or the private sector.